Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06034002 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

A Phase 1 study of Myeloproliferative Neoplasms, sponsored by Incyte Corporation.

Recruiting
Registry status
Phase 1
Development phase
230
Enrollment target
13
Study locations

NCT06034002 is a Phase 1 study of Myeloproliferative Neoplasms that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 230 participants, above the 123-participant average among 8 other Myeloproliferative Neoplasms trials with a reported enrollment target (87% higher). The trial reports 13 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06034002, a Phase 1 study of Myeloproliferative Neoplasms, is actively recruiting participants, sponsored by Incyte Corporation.

RECRUITING
Registry status
Phase 1
Development phase
230 participants
Enrollment target
13
Study locations

Study Summary

This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a Monotherapy or in Combination With Ruxolitinib in participants with myeloproliferative neoplasms.

Conditions Studied

Myeloproliferative Neoplasms

Interventions

  • DRUG Ruxolitinib
  • DRUG INCA033989

Study Locations (13)

California

  • City of Hope Medical Center - Duarte
  • Stanford Cancer Institute - Palo Alto

New York

  • Icahn School of Medicine At Mount Sinai - New York
  • Memorial Sloan Kettering Cancer Center - New York

Florida

  • University of Miami Health System - Miami

Kansas

  • The University of Kansas Cancer Center - Westwood

Maryland

  • Johns Hopkins Hospital - Baltimore

Massachusetts

  • Dana Farber Cancer Institute - Boston

Missouri

  • Washington University School of Medicine - St Louis

North Carolina

  • Wake Forest Baptist Medical Center - Winston-Salem

Trial Details

FieldValue
Enrollment Target 230 participants
Start Date 2023-12-04
Est. Completion 2028-10-29
Phase Phase 1

Sponsor

Incyte Corporation

239 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06034002

The ClinicalTrials.gov registry entry for NCT06034002 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 123-participant average among 8 other Myeloproliferative Neoplasms trials with a reported enrollment target (87% higher). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Myeloproliferative Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Ruxolitinib is the first listed.

NCT06034002 reports 13 study locations spanning 11 distinct geographic areas - top geographies include California, New York, Florida.

Frequently Asked Questions

What is clinical trial NCT06034002 about?

NCT06034002 is a clinical study titled "A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms". This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a Monotherapy or in Combination With Ruxolitinib in participants with myeloprol...

What is the current status of trial NCT06034002?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 230 participants. The study started on 2023-12-04. Estimated completion is 2028-10-29.

What conditions does trial NCT06034002 study?

This clinical trial studies the following conditions: Myeloproliferative Neoplasms.

What interventions are being tested in trial NCT06034002?

The interventions under investigation include: Ruxolitinib (DRUG), INCA033989 (DRUG).

Who is sponsoring clinical trial NCT06034002?

This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06034002 being conducted?

This trial has 13 study locations across California, Florida, Kansas, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Myeloproliferative Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Myeloproliferative Neoplasms

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.